In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- ‘A slippery slope’: Is AI eroding clinical skills? (Healio)
- ModMed Expands gGastro Suite With New AI Capabilities for Gastroenterology (Business Wire)
- CRH Anesthesia Announces Partnership with Associates in Gastroenterology Through Acquisition of Majority Interest in Southern Colorado Anesthesia Associates (CRH Medical)
- Bidirectional Text Navigation (ColoPrep) Increases Colonoscopy Show Rate (Gastro Hep Advances)
- Viome Launches CancerDetect® Pancreatic, Built For Early Pancreatic Cancer Detection (PR Newswire)
- Magnetically controlled capsule shows promise for investigating hard-to-reach regions of the small intestine (Medical Xpress)
- Successful Repeat Colonoscopy and Building an AI Databank (GI & Endoscopy News)
- What created GI’s anesthesia ‘dependency’ — and what comes next (Becker’s Healthcare)
